Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Global Blood Therapeutics stock in Canada | $34.90
Own Global Blood Therapeutics shares in just a few minutes.
Global Blood Therapeutics (GBT) is a leading biotechnology business based in the US. It opened the day at $34.2 after a previous close of $34.13. During the day the price has varied from a low of $33.99 to a high of $35.14. The latest price was $34.9 (25 minute delay). Global Blood Therapeutics is listed on the NASDAQ and employs 389 staff. All prices are listed in US Dollars.
How to buy Global Blood Therapeutics stock in Canada
- Choose a platform. If you're a beginner, our stock trading table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: GBT in this case.
- Research Global Blood Therapeutics stocks. The platform should provide the latest information available.
- Buy your Global Blood Therapeutics stocks. It's that simple.
What's in this guide?
- Can I buy shares in Global Blood Therapeutics?
- Has coronavirus impacted Global Blood Therapeutics shares?
- Global Blood Therapeutics shares summary
- Compare share dealing platforms
- Is Global Blood Therapeutics stock a buy or sell?
- Global Blood Therapeutics performance over time
- Can I short Global Blood Therapeutics shares?
- Global Blood Therapeutics's financials
- How volatile are Global Blood Therapeutics shares?
- Does Global Blood Therapeutics pay a dividend?
- Other common questions
How has Coronavirus impacted Global Blood Therapeutics's stock price?
Since the stock market crash in March caused by coronavirus, Global Blood Therapeutics's stock price has had significant negative movement.
Its last market close was $38.43, which is 47.13% down on its pre-crash value of $72.69 and 3.96% down on the lowest point reached during the March crash when the stocks fell as low as $39.95.
If you had bought $1,000 worth of Global Blood Therapeutics stocks at the start of February 2020, those stocks would have been worth $683.40 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $583.75.
Global Blood Therapeutics stock priceUse our graph to track the performance of GBT stocks over time.
Global Blood Therapeutics stocks at a glance
|52-week range||$27.1 - $71.23|
|50-day moving average||$34.062|
|200-day moving average||$40.7876|
|Wall St. target price||$78.47|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.645|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Global Blood Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Global Blood Therapeutics price performance over time
|1 month (2021-07-02)||1.48%|
|3 months (2021-05-04)||-10.47%|
Global Blood Therapeutics financials
|Revenue TTM||USD$148.7 million|
|Gross profit TTM||USD$121.8 million|
|Return on assets TTM||-21.75%|
|Return on equity TTM||-56.26%|
|Market capitalisation||USD$1.7 billion|
TTM: trailing 12 months
How to short and sell Global Blood Therapeutics stocks
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "GBT.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 12.2 million Global Blood Therapeutics stocks held short by investors – that's known as Global Blood Therapeutics's "short interest". This figure is 2.5% down from 12.5 million last month.
There are a few different ways that this level of interest in shorting Global Blood Therapeutics stocks can be evaluated.
Global Blood Therapeutics's "short interest ratio" (SIR)
Global Blood Therapeutics's "short interest ratio" (SIR) is the quantity of Global Blood Therapeutics stocks currently shorted divided by the average quantity of Global Blood Therapeutics stocks traded daily (recently around 1.5 million). Global Blood Therapeutics's SIR currently stands at 8.13. In other words for every 100,000 Global Blood Therapeutics stocks traded daily on the market, roughly 8130 stocks are currently held short.
However Global Blood Therapeutics's short interest can also be evaluated against the total number of Global Blood Therapeutics stocks, or, against the total number of tradable Global Blood Therapeutics stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Global Blood Therapeutics's short interest could be expressed as 0.2% of the outstanding stocks (for every 100,000 Global Blood Therapeutics stocks in existence, roughly 200 stocks are currently held short) or 0.2472% of the tradable stocks (for every 100,000 tradable Global Blood Therapeutics stocks, roughly 247 stocks are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Global Blood Therapeutics.
Find out more about how you can short Global Blood Therapeutics stock.
Global Blood Therapeutics stock dividends
We're not expecting Global Blood Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
Global Blood Therapeutics stock price volatility
Over the last 12 months, Global Blood Therapeutics's stocks have ranged in value from as little as $27.1 up to $71.23. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Global Blood Therapeutics's is 1.031. This would suggest that Global Blood Therapeutics's stocks are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Global Blood Therapeutics overview
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. The company was founded in 2011 and is headquartered in South San Francisco, California.
Stocks similar to Global Blood Therapeutics
Global Blood Therapeutics in the news
Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q2 2021 Results - Earnings Call Transcript
Global Blood Therapeutics (GBT) Reports Q2 Loss, Tops Revenue Estimates
GBT Reports Second Quarter 2021 Financial Results
Frequently asked questions
More guides on Finder
How to buy Wheels Up (UP) stock in Canada when it goes public
Everything we know about the Wheels Up IPO, plus information on how to buy in.
How to invest $1 million
Here are the top 5 ways you should invest $1 million.
How to buy Brookfield Asset Management Reinsurance Partners Ltd (BAMR) stock in Canada when it goes public
Everything we know about the Brookfield Asset Management Reinsurance Partners Ltd IPO, plus information on how to buy in.
How to buy Traeger (COOK) stock in Canada
Everything we know about the Traeger IPO, plus information on how to buy in.
How to buy Teads (TEAD) stock in Canada when it goes public
Everything we know about the Teads IPO, plus information on how to buy in.
How to buy Snap One Holdings Corp (SNPO) stock in Canada
Everything we know about the Snap One Holdings Corp IPO, plus information on how to buy in.
How to buy Riskified (RSKD) stock in Canada
Everything we know about the Riskified IPO, plus information on how to buy in.
How to buy Preston Hollow Community Capital (PHCC) stock in Canada when it goes public
Everything we know about the Preston Hollow Community Capital IPO, plus information on how to buy in.
How to buy PowerSchool Holdings (PWSC) stock in Canada
Everything we know about the PowerSchool Holdings IPO, plus information on how to buy in.
How to buy MeridianLink (MLNK) stock in Canada
Everything we know about the MeridianLink IPO, plus information on how to buy in.
Ask an Expert
You must be logged in to post a comment.